Business
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation.
About this update from Decoy Therapeutics Inc.
[{"type":"text","content":"Access the "What This Means" segment here","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation.","length":449,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":104,"url":"https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9Rx5QeyO4QyCQkFqooOe9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a","width":400,"height":104}},"href":"https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The "What This Means" segment provides additional context on Decoy's plans to develop a flexible, globally accessible, and scalable manufacturing platform for peptide-conjugate antivirals, a key funded development under the Company's agreement with the Gates Foundation. The platform is designed to enable rapid, cost-efficient manufacturing and scale-up of therapeutics developed through Decoy's proprietary IMP3ACT™ platform, with a focus on expanding access in low- and middle-income countries.","length":519,"tagName":"p"},{"type":"text","content":"As part of the segment, Peter Marschel, Chief Business Officer of Decoy, discussed how the Company's "design-for-manufacturing" approach supports the rapid transition of peptide-conjugate therapeutics from laboratory development to commercial-scale production and is designed to enable a distributed global manufacturing network capable of responding to emerging viral threats. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor, which is funde...